title: Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
authors.forename: Georg
authors.initials: G
authors.lastname: Röggla
authors.forename: Bernadetta
authors.initials: B
authors.lastname: Moser
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000941:ethics; D016265:Conflict of Interest; D017277:Drug Approval; D004345:Drug Industry / Q000941:ethics*; D026822:Ethicists; D040861:Ethics, Business; D004994:Ethics, Pharmacy; D005060:Europe; D006801:Humans; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000517:prevention & control*; D014481:United States
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated